PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:MD • US58502B1061
20.76 USD
-0.13 (-0.62%)
Last: Feb 10, 2026, 09:49 AM
Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. MD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make MD a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- MD had positive earnings in the past year.
- MD had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
- MD has a better Return On Assets (7.37%) than 89.22% of its industry peers.
- The Return On Equity of MD (18.21%) is better than 87.25% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 10.25%, MD belongs to the top of the industry, outperforming 80.39% of the companies in the same industry.
- MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.11%.
- The 3 year average ROIC (7.83%) for MD is below the current ROIC(10.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
- With an excellent Profit Margin value of 8.44%, MD belongs to the best of the industry, outperforming 89.22% of the companies in the same industry.
- The Operating Margin of MD (12.20%) is better than 83.33% of its industry peers.
- MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for MD has been increased compared to 1 year ago.
- Compared to 5 years ago, MD has more shares outstanding
- MD has a worse debt/assets ratio than last year.
2.2 Solvency
- MD has an Altman-Z score of 2.15. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score of 2.15. This is comparable to the rest of the industry: MD outperforms 53.92% of its industry peers.
- MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
- MD has a Debt to FCF ratio of 2.20. This is in the better half of the industry: MD outperforms 78.43% of its industry peers.
- A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
- MD's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. MD outperforms 55.88% of its industry peers.
- Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.15 |
ROIC/WACC1.16
WACC8.81%
2.3 Liquidity
- A Current Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
- MD has a better Current ratio (1.83) than 71.57% of its industry peers.
- A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
- With a decent Quick ratio value of 1.83, MD is doing good in the industry, outperforming 74.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
- The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
- MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
- Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 7.64% on average per year.
- MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.71% yearly.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 10.18, the valuation of MD can be described as reasonable.
- 91.18% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (28.06), we can say MD is valued rather cheaply.
- With a Price/Forward Earnings ratio of 9.21, the valuation of MD can be described as very reasonable.
- MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 92.16% of the companies in the same industry.
- MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.18 | ||
| Fwd PE | 9.21 |
4.2 Price Multiples
- MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 85.29% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MD is valued cheaply inside the industry as 92.16% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.52 | ||
| EV/EBITDA | 7.03 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
- A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
- MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:MD (2/10/2026, 9:49:10 AM)
20.76
-0.13 (-0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners98.9%
Inst Owner Change-0.29%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.78B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (11.37%)
Short Float %3.62%
Short Ratio3.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.45%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.18 | ||
| Fwd PE | 9.21 | ||
| P/S | 0.93 | ||
| P/FCF | 6.52 | ||
| P/OCF | 6.15 | ||
| P/B | 2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.03 |
EPS(TTM)2.04
EY9.83%
EPS(NY)2.25
Fwd EY10.85%
FCF(TTM)3.18
FCFY15.33%
OCF(TTM)3.38
OCFY16.27%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.23
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.15 |
F-Score8
WACC8.81%
ROIC/WACC1.16
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.18 and the Price/Book (PB) ratio is 2.